Document is current
Any future updates will be listed below
-
Authors
Dyer, Arthur
Dudley, Rebecca
Ahuja, Shreya
Alsinet, Clara
Poudel, Pawan
Bowyer, Georgina
Sahota, Kalvin
Songvilay, Saly
Jones, Des C.
Glover, Matthew
Hess, Sonja
Timosenko, Elina
Dovedi, Simon J.
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 23 November 2025
First Online: 28 November 2025
Declarations
:
: At the time this study was conducted, A.D, R.D, S.A, C.A, P.P, G.B, K.S, S.S, D.J, M.G, S.H, E.T, and S.D. were employees of AstraZeneca, with stock ownership and/or stock options or interests in the company.
: The study is being performed in accordance with consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, all applicable laws and regulations, and the AstraZeneca policy on Bioethics and Human Biological Samples. Human PBMCs were obtained from leucocyte cones, which are by- products of the apheresis process of blood donated by healthy individuals to the National Health Service Blood and Transplant (NHSBT). Donors give generic consent for research use and are not identifiable. For ascites samples, an independent cohort of patients was recruited prospectively in Central Europe between June 2021 and November 2021 through a commercial biospecimen procurement service (Discovery Life Sciences, IRB approval no. DLS-BB044-V.1) in full compliance with UK and US regulations and fully consented for research use by the donors with informed written consent. The experimental protocols were approved by Discovery Life Sciences LLC.
